pharma · Ovarian Neoplasms · Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer
TESARO Bio Netherlands
TESARO Bio Netherlands B.V.
TESARO Bio Netherlands patent portfolio — 0 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- EU
- Programs
- 6
- Drugs
- 23
- Patents
- 0
TESARO Bio Netherlands patents
0 pharmaceutical patents indexed for TESARO Bio Netherlands. 0 expire within 24 months.
TESARO Bio Netherlands has 0 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
No patents matched
Frequently asked questions
How many patents does TESARO Bio Netherlands have?
0 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do TESARO Bio Netherlands patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.